Sensei Biotherapeutics, Inc.
SNSE
$21.45
$0.452.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -61.50% | -27.34% | -16.55% | -6.92% | -24.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.52% | -37.99% | -33.14% | -16.68% | -12.22% |
| Operating Income | 55.52% | 37.99% | 33.14% | 16.68% | 12.22% |
| Income Before Tax | 39.29% | 37.01% | 30.89% | 14.11% | -4.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.29% | 37.01% | 30.89% | 14.11% | -4.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.29% | 37.01% | 30.89% | 14.11% | -4.80% |
| EBIT | 55.52% | 37.99% | 33.14% | 16.68% | 12.22% |
| EBITDA | 53.90% | 35.70% | 30.70% | 13.80% | 12.74% |
| EPS Basic | 39.44% | 37.20% | 31.20% | 14.60% | -4.05% |
| Normalized Basic EPS | 56.13% | 37.22% | 31.76% | 12.41% | 8.31% |
| EPS Diluted | 39.44% | 37.20% | 31.20% | 14.60% | -4.05% |
| Normalized Diluted EPS | 56.13% | 37.22% | 31.76% | 12.41% | 8.31% |
| Average Basic Shares Outstanding | 0.25% | 0.32% | 0.46% | 0.57% | 0.72% |
| Average Diluted Shares Outstanding | 0.25% | 0.32% | 0.46% | 0.57% | 0.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |